Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link

Volume 31, Number 12—December 2025

Online Report

Diphtheria Antitoxin Production and Procurement Practices and Challenges

Caroline MarshallComments to Author , William Perea Caro1, Alejandro Costa, Lee Lee Ho, Peter J. Gardner, Christophe Guitton1, Julien Potet, and Erin Sparrow1Comments to Author 
Author affiliation: London School of Hygiene & Tropical Medicine Faculty of Epidemiology and Public Health, London, UK (C. Marshall); World Health Organization, Geneva, Switzerland (C. Marshall, W.P. Caro, A. Costa, L.L. Ho, C. Guitton, E. Sparrow); Wellcome Trust, London, UK (P.J. Gardner); Médecins Sans Frontières, Paris, France (J. Potet)

Main Article

Figure

Development of S315, a human monoclonal antibody produced through the isolation of antibody-secreting cells in human volunteers boosted with a combination tetanus/diphtheria vaccine. Antibody-producing genes are amplified, synthesized, and screened through antibody binding and toxin neutralization.

Figure. Development of S315, a human monoclonal antibody produced through the isolation of antibody-secreting cells in human volunteers boosted with a combination tetanus/diphtheria vaccine. Antibody-producing genes are amplified, synthesized, and screened through antibody binding and toxin neutralization.

Main Article

1Retired.

Page created: September 26, 2025
Page updated: January 01, 2026
Page reviewed: January 01, 2026
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
file_external